Michal Abraham

Israel Institute for Biological Research — Israel

Medicine · Health Sciences

28h-index2.2kcitations116works0.12yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chemokine receptors and signaling(38), Immunotherapy and Immune Responses(31), Multiple Myeloma Research and Treatments(27), Immune Cell Function and Interaction(14), Chronic Lymphocytic Leukemia Research(14)

Publications116 total

THE ROLE OF MEDICAL LABORATORY TECHNOLOGY IN MONITORING THERAPEUTIC DRUG LEVELS AND MINIMIZING ADVERSE DRUG REACTIONS

Journal of Applied Bioanalysis·2025Open Access

Abstract A056: Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway in Pancreatic Cancer

Cancer Research·2025

Abstract 6874: Bkt300, a novel small molecule targeting the protein regulator of cytokinesis 1 pathway in hepatocellular carcinoma

Cancer Research·2025Open Access

Identification of Dinaciclib and Ganetespib as anti-inflammatory drugs using a novel HTP screening assay that targets IFNγ-dependent PD-L1

1 cited

Frontiers in Immunology·2025· 1 citedOpen Access

BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway

2025Open Access

Precision Drug Delivery to The Colon: A Review of Modern Approaches”

African Journal of Biomedical Research·2025Open Access

WED-534 MiR122 expression regulates liver immune tolerance and microenvironment

Journal of Hepatology·2024

Abstract 674: Novel anti-cancer small molecule targeting the protein regulator of cytokinesis pathway

Cancer Research·2024

Data from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo

2023Open Access

Supplementary Figure 2 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo

2023Open Access

Supplementary Figure 2 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo

2023Open Access

Supplementary Figure 1 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo

2023Open Access

Supplementary Figure 1 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo

2023Open Access

Data from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo

2023Open Access

Supplementary Table 1 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo

2023Open Access

Supplementary Table 1 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo

2023Open Access

Figure S5 from CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1–Mediated ERK and BCL2/Cyclin D1 Pathways

2023Open Access

Table S3 from Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers

2023Open Access

Figure S1 from CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1–Mediated ERK and BCL2/Cyclin D1 Pathways

2023Open Access

Data from The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma

2023Open Access

page 1 of 6Next →

Frequent Co-authors

Amnon Peled(41), Hanna Wald(30), Katia Beider(27), Arnon Nagler(23), Orly Eizenberg(22), Eithan Galun(21), Ori Wald(17), Ido D. Weiss(16), Yaron Pereg(9), Shiri Klein(8), Lola Weiss(8), Howard L. Weiner(6), Arnon Karni(6), Baruch Bulvik(6), Avichai Shimoni(6), Ariel Miller(5), Maya Koren‐Michowitz(5), Devorah Olam(5), Abi Vainstein(5), Arnon Aharon(5)